News

ODI Pharma AB (“ODI” or “the Company”) gives an update regarding that a MAR label was missing in the quarterly report published 28th of M...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report for the period July 2019 – March 2020. The report is available...

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Board of Directors does not see any impact on the Company’s mid- and lon...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is avai...

ODI Pharma AB (“ODI Pharma” or “the Company”) hereby announce that Aphria Inc. (“Aphria”), the Company’s supplier of medical cannabis, ha...

Stockholm, 20.01.2020. As communicated earlier today, ODI Pharma AB's (“ODI Pharma” or “Company”) recently completed new share issue has ...

Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed an...

The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was com...

ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been ap...

Zug/Switzerland, August 2nd, 2019 - The board of ODI Pharma Schweiz AG announces that its operations will be consolidated shortly under a...